Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q2 FY2026 Earnings Presentation
19 slides from Gland Pharma's earnings presentation, Nov 3, 2025
Slide 1: Exchange filing cover letter
November 03, 2025 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor 25th floor, Dalal Street Plot no. C-1, Block G, Bandra Kurla Complex Bandra Mumbai - 400 001 (East), Mumbai - 400 051 Scrip
Slide 2: Investor Presentation Q2FY26
GLAND PHARMA Investor Presentation Q2FY26 03 November 2025
Slide 3: Safe Harbour Statement
Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendatio
Slide 4: Financial Highlights
in Financial Highlights
Slide 5: Consolidated P&L Highlights
Consolidated P&L Highlights ₹ Mn Particulars Q2 FY26 Q2 FY25 YoY Q1 FY26 QoQ 6M FY26 6M FY25 YoY Revenue from operations 14,869 14,058 6% 15,056 -1% 29,925 28,075 7% Other Income 842 596 41% 575 46% 1,417 1,111 28% Total Income 15,710 14,654 7% 15,631 1% 31,342 29,186 7% Gross Profit(1) 9,331 8,304
Slide 6: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (₹ Mn) (₹ Mn / %) 29,925 19,175 28,075 16,678 64% 59% 15,056 14,869 9,845 9,331 14,058 8,304 65% 63% 59% Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M FY26 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M FY26 EBITDA (3) / E
Slide 7: Base Business (Gland) P&L Highlights
Base Business (Gland) P&L Highlights ₹ Mn Particulars Q2 FY26 Q2 FY25 YoY Q1 FY26 QoQ 6M FY26 6M FY25 YoY Revenue from operations 10,767 10,659 1% 10,409 3% 21,176 20,793 2% Other Income 861 595 45% 556 55% 1,417 1,088 30% Total Income 11,628 11,254 3% 10,965 6% 22,593 21,881 3% Gross Profit(1) 6,57
Slide 8: Base Business (Gland) Financial Highlights
Base Business (Gland) Financial Highlights Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (₹ Mn) (₹ Mn / %) 20,793 21,176 12,715 11,305 60% 54% 10,659 10,409 10,767 5,957 6,144 6,571 59% 61% 56% Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M FY26 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M FY26 EBITD
Slide 9: Group Financial Highlights (1/2)
Group Financial Highlights (1/2) Net Worth (1) ROCE (2) / RONW (3) (₹ Mn) (%) RoCE RoNW 87,238 91,507 95,626 11% 15.00% 9% 8% 10.00% 9% 8% 8% 5.00% 0.00% FY24 FY25 6M FY26 FY24 FY25 6M FY26 Capital Expenditure Asset Turnover Ratio (4)(5) (₹ Mn) (x) 3,975 3,938 1.5 1.4 1.4 1,969 0.6 0.5 0.5 Total ass
Slide 10: Group Financial Highlights (2/2)
Group Financial Highlights (2/2) Cash and Bank Balances / Net Cash (1) Cash Flow from Operations (₹ Mn) Total Cash (₹ Mn) Net Cash 9,968 25,562 27,039 9,147 22,870 24,484 18,394 5,933 15,197 FY24 FY25 * 6M FY26 * FY24 FY25 6M FY26 . * Excluding non-callable deposits of INR 3,960 million. Net Working
Slide 11: Business Update
in Business Update
Slide 12: Base Business (Gland) Updates
Base Business (Gland) Updates • R&D Expenses: Total R&D expenses were ₹614 million in Q2 FY26, representing 5.8% of revenue versus ₹460 million in Q1 FY26. • New Launches: The company launched seven molecules in the USA this quarter, including Daptomycin-RTU, Sumatriptan, new strength of Colistimeth
Slide 13: Cenexi Updates
Cenexi Updates Q2 FY26 Q2 FY25 Q1 FY26 6M FY26 6M FY25 Particulars YoY QoQ YoY € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. Revenue from operations 40 4,102 37 3,399 21% 48 4,648 -12% 88 8,750 80 7,282 20% Gross Margin 27 2,760 25 2,347 18% 38 3,701 -25% 65 6,461 59 5,373 20% % margin
Slide 14: Geographical Revenue
SS Geographical — Revenue |
Slide 15: US Market
US Market ₹ Mn Group Revenue Contribution Gland Cenexi 10% YoY 4% YoY 8% YoY 2% YoY 77% YoY 112% YoY 15,175 15,722 14,917 15,176 546 7,547 7,443 8,279 7,393 7,170 8,005 273 274 258 155 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M FY26 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M FY26 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M
Slide 16: Europe Market
Europe Market ₹ Mn Group Revenue Contribution Gland Cenexi 16% YoY 22% YoY -42% YoY 12% YoY 25% YoY 24% YoY 828 5,322 6,150 736 4,289 5,025 639 3,302 2,847 2,663 2,658 2,459 329 2,130 189 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M FY26 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M FY26 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25
Slide 17: Other Core Markets (Canada, Australia and New Zealand)
Other Core Markets (Canada, Australia and New Zealand) ₹ Mn Group Revenue Contribution Gland Cenexi -5% YoY 28% YoY -33% YoY 24% YoY 95% YoY 33% YoY 746 1,227 481 600 962 473 362 739 405 266 515 488 273 215 110 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M FY26 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25 6M FY26 Q2 FY25 Q
Slide 18: Rest of the World
Rest of the World ₹ Mn Group Revenue Contribution Gland Cenexi -3% YoY 1% YoY -1% YoY 1% YoY -5% YoY 1% YoY Own Products 5,512 5,568 TT & CMO 3,139 3,168 378 2,373 2,400 797 2,663 2,978 2,590 1,658 1,533 1,635 1,445 232 142 1,005 955 236 2,790 2,342 1,426 1,297 1,493 Q2 FY25 Q1 FY26 Q2 FY26 6M FY25
Slide 19: Thank You
GLAND PHARMA Thank You Corporate Office Investor Relations: Gland Pharma Limited Sampath Kumar Pallerlamudi Plot No. 11 & 84, TSIIC Phase: IV Company Secretary & Compliance Officer Pashamylaram (V), Patancheru (M), Sangareddy District Shriniwas P. Dange Hyderabad 502307, Telangana, India Investor Re